1
|
Hackert MQN, Ankersmid JW, Engels N, Prick JCM, Teerenstra S, Siesling S, Drossaert CHC, Strobbe LJA, van Riet YEA, van den Dorpel RMA, Bos WJW, van der Nat PB, van den Berg-Vos RM, van Schaik SM, Garvelink MM, van der Wees PJ, van Uden-Kraan CF. Effectiveness and implementation of SHared decision-making supported by OUTcome information among patients with breast cancer, stroke and advanced kidney disease: SHOUT study protocol of multiple interrupted time series. BMJ Open 2022; 12:e055324. [PMID: 35914919 PMCID: PMC9345077 DOI: 10.1136/bmjopen-2021-055324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
INTRODUCTION Within the value-based healthcare framework, outcome data can be used to inform patients about (treatment) options, and empower them to make shared decisions with their health care professional. To facilitate shared decision-making (SDM) supported by outcome data, a multicomponent intervention has been designed, including patient decision aids on the organisation of post-treatment surveillance (breast cancer); discharge location (stroke) and treatment modality (advanced kidney disease), and training on SDM for health care professionals. The SHared decision-making supported by OUTcome information (SHOUT) study will examine the effectiveness of the intervention and its implementation in clinical practice. METHODS AND ANALYSIS Multiple interrupted time series will be used to stepwise implement the intervention. Patients diagnosed with either breast cancer (N=630), stroke (N=630) or advanced kidney disease (N=473) will be included. Measurements will be performed at baseline, three (stroke), six and twelve (breast cancer and advanced kidney disease) months. Trends on outcomes will be measured over a period of 20 months. The primary outcome will be patients' perceived level of involvement in decision-making. Secondary outcomes regarding effectiveness will include patient-reported SDM, decisional conflict, role in decision-making, knowledge, quality of life, preferred and chosen care, satisfaction with the intervention, healthcare utilisation and health outcomes. Outcomes regarding implementation will include the implementation rate and a questionnaire on the health care professionals' perspective on the implementation process. ETHICS AND DISSEMINATION The Medical research Ethics Committees United in Nieuwegein, the Netherlands, has confirmed that the Medical Research Involving Human Subjects Act does not apply to this study. Bureau Onderzoek & Innovatie of Santeon, the Netherlands, approved this study. The results will contribute to insight in and knowledge on the use of outcome data for SDM, and can stimulate sustainable implementation of SDM. TRIAL REGISTRATION NUMBER NL8374, NL8375 and NL8376.
Collapse
Affiliation(s)
| | - Jet W Ankersmid
- Santeon Hospital Group, Utrecht, The Netherlands
- Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | - Noel Engels
- Santeon Hospital Group, Utrecht, The Netherlands
- Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands
| | - Janine C M Prick
- Santeon Hospital Group, Utrecht, The Netherlands
- Neurology, OLVG, Amsterdam, The Netherlands
| | - Steven Teerenstra
- Radboud Institute for Health Sciences, Health Evidence, section Biostatistics, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - Sabine Siesling
- Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands
- Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | | | - Luc J A Strobbe
- Surgical Oncology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
| | | | | | - Willem Jan W Bos
- Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands
- Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands
| | - Paul B van der Nat
- Value-Based Health Care, St. Antonius Hospital, Nieuwegein, The Netherlands
- Radboud Institute for Health Sciences, Scientific Centre for Quality of Healthcare (IQ Healthcare), Radboud University Medical Centre, Nijmegen, The Netherlands
| | - Renske M van den Berg-Vos
- Neurology, OLVG, Amsterdam, The Netherlands
- Neurology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands
| | | | - Mirjam M Garvelink
- Value-Based Health Care, St. Antonius Hospital, Nieuwegein, The Netherlands
| | - Philip J van der Wees
- Radboud Institute for Health Sciences, Scientific Centre for Quality of Healthcare (IQ Healthcare), Radboud University Medical Centre, Nijmegen, The Netherlands
- Radboud Institute for Health Sciences, Rehabilitation, Radboud University Medical Centre, Nijmegen, The Netherlands
| | | |
Collapse
|
2
|
Engels N, van der Nat PB, Ankersmid JW, Prick JCM, Parent E, The R, Takahashi A, Bart HAJ, van Uden-Kraan CF, Stiggelbout AM, Bos WJW, van den Dorpel MA. Development of an online patient decision aid for kidney failure treatment modality decisions. BMC Nephrol 2022; 23:236. [PMID: 35794539 PMCID: PMC9257566 DOI: 10.1186/s12882-022-02853-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 06/16/2022] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Patient decision aids (PtDAs) support patients and clinicians in shared decision-making (SDM). Real-world outcome information may improve patients’ risk perception, and help patients make decisions congruent with their expectations and values. Our aim was to develop an online PtDA to support kidney failure treatment modality decision-making, that: 1) provides patients with real-world outcome information, and 2) facilitates SDM in clinical practice.
Methods
The International Patient Decision Aids Standards (IPDAS) development process model was complemented with a user-centred and convergent mixed-methods approach. Rapid prototyping was used to develop the PtDA with a multidisciplinary steering group in an iterative process of co-creation. The results of an exploratory evidence review and a needs-assessment among patients, caregivers, and clinicians were used to develop the PtDA. Seven Dutch teaching hospitals and two national Dutch outcome registries provided real-world data on selected outcomes for all kidney failure treatment modalities. Alpha and beta testing were performed to assess the prototype and finalise development. An implementation strategy was developed to guide implementation of the PtDA in clinical practice.
Results
The ‘Kidney Failure Decision Aid’ consists of three components designed to help patients and clinicians engage in SDM: 1) a paper hand-out sheet, 2) an interactive website, and 3) a personal summary sheet. A ‘patients-like-me’ infographic was developed to visualise survival probabilities for each treatment modality on the website. Other treatment outcomes were incorporated as event rates (e.g. hospitalisation rates) or explained in text (e.g. the flexibility of each treatment modality). No major revisions were needed after alpha and beta testing. During beta testing, some patients ignored the survival probabilities because they considered these too confronting. Nonetheless, patients agreed that every patient has the right to choose whether they want to view this information. Patients and clinicians believed that the PtDA would help patients make informed decisions, and that it would support values- and preferences-based decision-making. Implementation of the PtDA has started in October 2020.
Conclusions
The ‘Kidney Failure Decision Aid’ was designed to facilitate SDM in clinical practice and contains real-world outcome information on all kidney failure treatment modalities. It is currently being investigated for its effects on SDM in a clinical trial.
Collapse
|
3
|
Prick JCM, Zonjee VJ, van Schaik SM, Dahmen R, Garvelink MM, Brouwers PJAM, Saxena R, Keus SHJ, Deijle IA, van Uden-Kraan CF, van der Wees PJ, Van den Berg-Vos RM. Experiences with information provision and preferences for decision making of patients with acute stroke. Patient Educ Couns 2022; 105:1123-1129. [PMID: 34462248 DOI: 10.1016/j.pec.2021.08.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 07/23/2021] [Accepted: 08/21/2021] [Indexed: 06/13/2023]
Abstract
OBJECTIVE The aim of this study was to gain insight into experiences of patients with acute stroke regarding information provision and their preferred involvement in decision-making processes during the initial period of hospitalisation. METHODS A sequential explanatory design was used in two independent cohorts of patients with stroke, starting with a survey after discharge from hospital (cohort 1) followed by observations and structured interviews during hospitalisation (cohort 2). Quantitative data were analysed descriptively. RESULTS In total, 72 patients participated in this study (52 in cohort 1 and 20 in cohort 2). During hospitalisation, the majority of the patients were educated about acute stroke and their treatment. Approximately half of the patients preferred to have an active role in the decision-making process, whereas only 21% reported to be actively involved. In cohort 2, 60% of the patients considered themselves capable to carefully consider treatment options. CONCLUSIONS Active involvement in the acute decision-making process is preferred by approximately half of the patients with acute stroke and most of them consider themselves capable of doing so. However, they experience a limited degree of actual involvement. PRACTICE IMPLICATIONS Physicians can facilitate patient engagement by explicitly emphasising when a decision has to be made in which the patient's opinion is important.
Collapse
Affiliation(s)
- J C M Prick
- Department of Neurology, OLVG, Amsterdam, The Netherlands; Santeon, Utrecht, The Netherlands.
| | - V J Zonjee
- Department of Neurology, OLVG, Amsterdam, The Netherlands
| | - S M van Schaik
- Department of Neurology, OLVG, Amsterdam, The Netherlands
| | - R Dahmen
- Amsterdam Rehabilitation Research Center/Reade, Amsterdam, The Netherlands
| | - M M Garvelink
- Department of Value Based Healthcare, St. Antonius Hospital, Nieuwegein, The Netherlands
| | - P J A M Brouwers
- Department of Neurology, Medisch Spectrum Twente, Enschede, The Netherlands
| | - R Saxena
- Department of Neurology, Maasstad Ziekenhuis, Rotterdam, The Netherlands
| | - S H J Keus
- Department of Quality and Improvement, OLVG, Amsterdam, The Netherlands
| | - I A Deijle
- Department of Quality and Improvement, OLVG, Amsterdam, The Netherlands
| | | | - P J van der Wees
- Radboud Institute for Health Sciences, IQ Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands
| | - R M Van den Berg-Vos
- Department of Neurology, OLVG, Amsterdam, The Netherlands; Department of Neurology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands
| |
Collapse
|
4
|
Ankersmid JW, Siesling S, Strobbe LJA, Bode-Meulepas JM, van Riet YEA, Engels N, Prick JCM, The R, Takahashi A, Velting M, van Uden-Kraan CF, Drossaert CHC. Supporting shared decision making about surveillance after breast cancer with personalised recurrence risk calculations: the development of a patient decision aid using the IPDAS development process in combination with a mixed-methods design (Preprint). JMIR Cancer 2022; 8:e38088. [DOI: 10.2196/38088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Revised: 09/14/2022] [Accepted: 09/16/2022] [Indexed: 11/13/2022] Open
|
5
|
Shepherd MS, Li J, Wilson NK, Oedekoven CA, Li J, Belmonte M, Fink J, Prick JCM, Pask DC, Hamilton TL, Loeffler D, Rao A, Schröder T, Göttgens B, Green AR, Kent DG. Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal. Blood 2018; 132:791-803. [PMID: 29991556 PMCID: PMC6107881 DOI: 10.1182/blood-2017-12-821066] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 07/03/2018] [Indexed: 12/24/2022] Open
Abstract
Recent advances in single-cell technologies have permitted the investigation of heterogeneous cell populations at previously unattainable resolution. Here we apply such approaches to resolve the molecular mechanisms driving disease in mouse hematopoietic stem cells (HSCs), using JAK2V617F mutant myeloproliferative neoplasms (MPNs) as a model. Single-cell gene expression and functional assays identified a subset of JAK2V617F mutant HSCs that display defective self-renewal. This defect is rescued at the single HSC level by crossing JAK2V617F mice with mice lacking TET2, the most commonly comutated gene in patients with MPN. Single-cell gene expression profiling of JAK2V617F-mutant HSCs revealed a loss of specific regulator genes, some of which were restored to normal levels in single TET2/JAK2 mutant HSCs. Of these, Bmi1 and, to a lesser extent, Pbx1 and Meis1 overexpression in JAK2-mutant HSCs could drive a disease phenotype and retain durable stem cell self-renewal in functional assays. Together, these single-cell approaches refine the molecules involved in clonal expansion of MPNs and have broad implications for deconstructing the molecular network of normal and malignant stem cells.
Collapse
Affiliation(s)
- Mairi S Shepherd
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Juan Li
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Nicola K Wilson
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Caroline A Oedekoven
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Jiangbing Li
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Miriam Belmonte
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Juergen Fink
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Janine C M Prick
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Dean C Pask
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Tina L Hamilton
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Dirk Loeffler
- Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland; and
| | - Anjana Rao
- La Jolla Institute and Department of Pharmacology, University of California, San Diego, La Jolla, CA
| | - Timm Schröder
- Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland; and
| | - Berthold Göttgens
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| | - Anthony R Green
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
- Department of Haematology, Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom
| | - David G Kent
- Wellcome MRC Cambridge Stem Cell Institute and
- Department of Haematology, University of Cambridge, United Kingdom
| |
Collapse
|
6
|
Schulte R, Wilson NK, Prick JCM, Cossetti C, Maj MK, Gottgens B, Kent DG. Index sorting resolves heterogeneous murine hematopoietic stem cell populations. Exp Hematol 2015; 43:803-11. [PMID: 26051918 PMCID: PMC4571925 DOI: 10.1016/j.exphem.2015.05.006] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Accepted: 05/07/2015] [Indexed: 12/17/2022]
Abstract
Recent advances in the cellular and molecular biology of single stem cells have uncovered significant heterogeneity in the functional properties of stem cell populations. This has prompted the development of approaches to study single cells in isolation, often performed using multiparameter flow cytometry. However, many stem cell populations are too rare to test all possible cell surface marker combinations, and virtually nothing is known about functional differences associated with varying intensities of such markers. Here we describe the use of index sorting for further resolution of the flow cytometric isolation of single murine hematopoietic stem cells (HSCs). Specifically, we associate single-cell functional assay outcomes with distinct cell surface marker expression intensities. High levels of both CD150 and EPCR associate with delayed kinetics of cell division and low levels of differentiation. Moreover, cells that do not form single HSC-derived clones appear in the 7AAD(dim) fraction, suggesting that even low levels of 7AAD staining are indicative of less healthy cell populations. These data indicate that when used in combination with single-cell functional assays, index sorting is a powerful tool for refining cell isolation strategies. This approach can be broadly applied to other single-cell systems, both to improve isolation and to acquire additional cell surface marker information.
Collapse
Affiliation(s)
- Reiner Schulte
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
| | - Nicola K Wilson
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
| | - Janine C M Prick
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom
| | - Chiara Cossetti
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
| | - Michal K Maj
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
| | - Berthold Gottgens
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
| | - David G Kent
- Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
| |
Collapse
|